Each year in the United States, thousands of patients suffering from end-stage renal failure undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. However, these powerful agents come with considerable risks on top of their important benefits. This report explores the differences in prescribing practices, attitudes, and perceptions of the general nephrologists, transplant nephrologists, and transplant surgeons involved in kidney patients’ continuum of care and uncovers potential opportunities in the marketing of current and future immunosuppressant therapies.
- What are the key drug classes used for induction and maintenance immunosuppressive regimens in kidney transplant patients?
- How do prescribers adjust induction and maintenance regimens if patients are not responding adequately?
- What are the key drivers and constraints of prescribing the most popular branded agents?
- What are prescribers’ estimates regarding patients’ compliance with current therapies?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Kidney Transplant - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Kidney Transplant US May 2019
Author(s): Tim Blackstock, MB, ChB, MPhil
Tim Blackstock, M.B. Ch.B., is a Director in Decision Resources Group’s Cardiovascular, Metabolic, Renal and Hematologic Disorders team focusing on dyslipidemia, obesity, and non-alcoholic steatohepatitis (NASH). In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets, as well as overseeing the work of team analysts across various metabolic and renal indications.
Tim holds a bachelor degrees in medicine and surgery from the University of Otago, New Zealand, and practiced medicine for five years, rotating through various specialties, including internal medicine, general surgery, and psychiatry. Prior to joining DRG, he was a writer in the medical communications industry, developing content for various media, as well as providing editorial assistance to leading pharmaceutical companies and medical experts across a variety of therapeutic areas.